VFA
PCVX icon

Values First Advisors’s Vaxcyte PCVX Stock Holding History

Values First Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Buy
6,768
+151
+2% +$8.2K 0.18% 131
2026
Q1 		$385K Buy
6,617
+1,937
+41% +$105K 0.2% 118
2025
Q4 		$216K Buy
+4,680
New +$209K 0.11% 161
2024
Q4 		– Sell
-1,527
Closed -$174K – 270
2024
Q3 		$174K Buy
+1,527
New +$138K 0.09% 155

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Values First Advisors's PCVX Position: Q2 2026 in Review

Values First Advisors increased its Vaxcyte (PCVX) stake by 2.3% in Q2 2026, buying an estimated $8.2K and bringing the position to 6,768 shares worth $393K. The position accounts for 0.18% of the portfolio, ranked #131.

Values First Advisors first reported a position in PCVX in Q3 2024 and has held it in 4 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Values First Advisors held 6,768 shares of Vaxcyte worth $393K as of Q2 2026.
  • Values First Advisors bought 151 Vaxcyte shares in Q2 2026, an estimated $8.2K.
  • Vaxcyte made up 0.18% of Values First Advisors's portfolio in Q2 2026, its #131 holding.
  • Values First Advisors first reported a position in Vaxcyte in Q3 2024 and has held it in 4 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Values First Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.